BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26254368)

  • 1. Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells.
    Hsu WC; Cheng CN; Lee TW; Hwang JJ
    Anticancer Res; 2015 Sep; 35(9):4777-88. PubMed ID: 26254368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
    Pan X; Lee RJ
    Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.
    Vega J; Ke S; Fan Z; Wallace S; Charsangavej C; Li C
    Pharm Res; 2003 May; 20(5):826-32. PubMed ID: 12751641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
    Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
    Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
    Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S
    Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-specific near-IR induced drug release and photothermal therapy with accumulated Au/Ag hollow nanoshells on pulmonary cancer cell membranes.
    Noh MS; Lee S; Kang H; Yang JK; Lee H; Hwang D; Lee JW; Jeong S; Jang Y; Jun BH; Jeong DH; Kim SK; Lee YS; Cho MH
    Biomaterials; 2015 Mar; 45():81-92. PubMed ID: 25662498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
    Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
    Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
    Elbayoumi TA; Torchilin VP
    Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.